Finerenone, a novel selective mineralocorticoid receptor antagonist, is an antifibrotic agent that showed promising results in lowering the risks of CKD progression and cardiovascular events in patients with CKD and type 2 diabetes [97]. The gene discussed is NR3C2; the disease is chronic kidney disease.